GoAI
Get started
MindWalk Holdings Corp. logo

MindWalk Holdings Corp.

HYFT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.41

+$0.04 · +2.92%

Aug 21, 4:00 PM ET

HYFT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

52

Fair Value

Momentum

31

Weakening

Sentiment

58

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jennifer Lynne Bath
Listed since
Jan 7, 2002
Employees
76

Market position

Day range

Current $1.41

52-week range

Current $1.41

Open
$1.38
Previous close
$1.37
Volume
73.5K
0.24× average
Average volume
306.75K
Average daily volume
Market cap
66.25M USD
Beta
0.82
Market reference 1
50-day average
$1.4406
-2.12% below average
200-day average
$1.5369
-8.26% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
67.15M CAD
P/E (TTM)
-6.39×
P/B (TTM)
7.76×
P/S (TTM)
5.92×
EV / EBITDA
-5.11×
Earnings yield
-18.32%
Free cash flow yield
-16.89%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
58.79%
Operating margin
-95.90%
Net margin
-89.63%
Return on equity
-117.10%
Return on assets
-64.36%
Return on invested capital
-89.17%

Financial health

Debt / equity
0.3×
Current ratio
2.8×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends78%3%-72%-147%Gross margin, FY2022: 56.72%Gross margin, FY2023: 55.95%Gross margin, FY2024: 49.16%Gross margin, FY2025: 55.25%Gross margin, FY2026: 58.80%Operating margin, FY2022: -86.10%Operating margin, FY2023: -123.93%Operating margin, FY2024: -56.13%Operating margin, FY2025: -49.74%Operating margin, FY2026: -96.01%Net margin, FY2022: -86.29%Net margin, FY2023: -128.53%Net margin, FY2024: -106.51%Net margin, FY2025: -123.30%Net margin, FY2026: -89.66%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 56.72%. Gross margin FY2023 55.95%. Gross margin FY2024 49.16%. Gross margin FY2025 55.25%. Gross margin FY2026 58.80%. Operating margin FY2022 -86.10%. Operating margin FY2023 -123.93%. Operating margin FY2024 -56.13%. Operating margin FY2025 -49.74%. Operating margin FY2026 -96.01%. Net margin FY2022 -86.29%. Net margin FY2023 -128.53%. Net margin FY2024 -106.51%. Net margin FY2025 -123.30%. Net margin FY2026 -89.66%.

Income trends

Revenue

15.32M CAD-37.52%

Operating income

−14.71M CAD-20.60%

Net income

−13.74M CAD+54.57%
Income trends across reported periods30M CAD8.09M CAD−13.81M CAD−35.71M CADRevenue, FY2022: 19.36M CADRevenue, FY2023: 20.67M CADRevenue, FY2024: 24.52M CADRevenue, FY2025: 24.52M CADRevenue, FY2026: 15.32M CADOperating income, FY2022: −16.67M CADOperating income, FY2023: −25.61M CADOperating income, FY2024: −13.76M CADOperating income, FY2025: −12.2M CADOperating income, FY2026: −14.71M CADNet income, FY2022: −16.71M CADNet income, FY2023: −26.56M CADNet income, FY2024: −26.12M CADNet income, FY2025: −30.23M CADNet income, FY2026: −13.74M CADFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 19.36M CAD. Revenue FY2023 20.67M CAD. Revenue FY2024 24.52M CAD. Revenue FY2025 24.52M CAD. Revenue FY2026 15.32M CAD. Operating income FY2022 −16.67M CAD. Operating income FY2023 −25.61M CAD. Operating income FY2024 −13.76M CAD. Operating income FY2025 −12.2M CAD. Operating income FY2026 −14.71M CAD. Net income FY2022 −16.71M CAD. Net income FY2023 −26.56M CAD. Net income FY2024 −26.12M CAD. Net income FY2025 −30.23M CAD. Net income FY2026 −13.74M CAD.
Metric (CAD)FY2026FY2025FY2024FY2023FY2022
Revenue15.32M CAD24.52M CAD24.52M CAD20.67M CAD19.36M CAD
Cost of goods sold6.31M CAD10.97M CAD12.47M CAD9.1M CAD8.38M CAD
Gross profit9.01M CAD13.55M CAD12.05M CAD11.56M CAD10.98M CAD
Research and development4.86M CAD4.94M CAD4.04M CAD14.1M CAD7.66M CAD
Selling, general, and administrative18.86M CAD19.03M CAD19.14M CAD18.99M CAD18.06M CAD
Operating expenses23.72M CAD25.74M CAD25.82M CAD37.17M CAD27.66M CAD
Interest income——23K CAD122K CAD279K CAD
Interest expense—9.91K CAD19K CAD30K CAD85K CAD
Depreciation and amortization1.58M CAD5.12M CAD5.74M CAD6.69M CAD3.77M CAD
Operating income−14.71M CAD−12.2M CAD−13.76M CAD−25.61M CAD−16.67M CAD
Net income−13.74M CAD−30.23M CAD−26.12M CAD−26.56M CAD−16.71M CAD

Company facts updated Aug 24, 2026.

HYFT news

gurufocus.com

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Read source
businesswire.com

MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ™, its biological context layer for AI…

Read source
prnewswire.com

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can

Read source
seekingalpha.com

MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript

MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript

Read source
zacks.com

MindWalk Holdings Corp. (HYFT) Reports Q4 Loss, Misses Revenue Estimates

MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.04 per share a year ago.

Read source
businesswire.com

MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for the fiscal year ended April 30, 2026. All figures are in…

Read source

HYFT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HYFT

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
200.87K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research HYFT

research.disclaimer